OneSource collaborates with Xbrane Biopharma AB
For commercial manufacturing of Xbrane's biosimilar portfolio
OneSource Specialty Pharma and Xbrane Biopharma AB, a Sweden-headquartered biotechnology company, today announced a partnership focused on the commercial manufacturing of Xbrane's biosimilar portfolio.
Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference products. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch.
As part of the agreement, Xbrane will tech transfer its select product(s) to OneSource's state-of the-art integrated Drug Substance and Drug Product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbrane's global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbrane's latest funding round, reinforcing the long-term alignment between the two companies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
15 minutes ago
- Business Standard
OneSource eyes weight-loss drug boost to order book
Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said on Monday. Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk and U.S.-based Eli Lilly. The active chemical compound in Novo's injectable Wegovy drug, semaglutide, will go off patent in 2026 in a few markets, including India. OneSource, which added 15 orders related to obesity and diabetes drugs in fiscal year 2025, said there are more in the pipeline. The global obesity market is estimated to be valued at $150 billion by the early 2030s. The company develops and manufactures complex biological drugs, vials, injectables, and soft gelatin capsules for larger pharmaceutical firms. "Our growth over the next few years will be driven by commercial launches of GLP-1s (weight-loss and diabetes drugs) by our global customers in all the key markets opening post patent expiry in 2026," CEO Neeraj Sharma told Reuters in an interview. Backed by increasing demand from weight-loss drug manufacturers, OneSource's order book across all service verticals should expand in line with 30% compound annual growth rate through fiscal year 2028, according to the CEO. OneSource, which competes with larger players such as Piramal Pharma and Divi's in contract research, development and manufacturing, is investing about $100 million to expand its drug device facilities, the CEO said. The company, which was demerged from Strides Pharma Science and listed in January, is also looking at setting up a global footprint in manufacturing, both in Europe and the U.S. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
3 hours ago
- Time of India
Polestar restarts market expansion with France
Swedish premium carmaker Polestar will start delivering its electric vehicles in France this year with the goal of making it one of its three main European markets, its top executive for the country told Reuters. Confronted with a cash crunch, tariff pressures, and a broad slowdown in EV demand, the company, majority-owned by China's Geely Holding, has decided to focus its efforts more on profitable Europe. Even there, though, its initial rapid expansion has stalled, with the last new market launches dating back to 2022. "We are a young company, given we have had a very steady rhythm of launches and market openings, it is good too, at some point to pause for a moment, before launching again a cycle of market openings", Stephane Le Guevel, managing director for Polestar France, said. "We have decided this year to concentrate on France and to restart the tempo next year. We have talked about Central Europe and LatAm", he said. While the Sweden-based automaker has attempted to conquer the U.S. and Chinese markets, its premium cars have been better received in Europe, which accounts for 75% of its sales. Le Guevel said that the automaker hoped France would, over the medium term, go on to become one of its top-selling markets in Europe, currently being Britain and Sweden. Polestar has tried to take on other premium brands, such as Mercedes, BMW, Audi, and Tesla, which it targeted in national ad campaigns seeking to entice Tesla owners to switch to Polestar. But its expansion has been on hold since it launched in Spain, Portugal and Italy about three years ago. In France, Polestar will start taking orders for its 2, 3 and 4 models on Wednesday, at starting prices ranging from 46,800 euros ($53,474) to 79,800 euros ($91,180). The first French showroom will open in Le Mans in July and first deliveries are expected from October. The company plans to have a robust servicing network and dedicated selling points still relying on its former owner Volvo Cars, which continues to manufacture some Polestar models . The company's French launch has been delayed by a complaint filed by PSA - now part of Stellantis - arguing the Polestar logo looked too much like the DS brand logo. Both parties reached an agreement in 2022 without disclosing its financial details.
Business Standard
6 hours ago
- Business Standard
Kellton Tech edges higher on stock split proposal; board to mull fund raising on June 14
Kellton Tech Solutions added 2.67% to Rs 130.55 after the company announced that its board will meet on Saturday, 14 June 2025, to consider a proposal for sub-division or split of existing equity shares of the company. During the same meeting, the board will also consider a proposal for raising funds through the issuance of equity or debt securities. These securities would either be privately placed, allotted on a preferential basis, or placed with qualified institutional investors. Hyderabad-headquartered Kellton Tech Solutions offers digital solutions, advisory services and serving as systems integrator to over 300 clients globally, ranging from start-ups to Fortune 500 enterprises. The company has a global footprint in India, the US, the UK, Ireland, Poland and Singapore with around 1,400 employees. The company had reported 19.77% decline in consolidated net profit to Rs 19.20 crore despite a 15.53% increase in net sales to Rs 286.33 crore in Q4 FY25 as compared with Q4 FY24.
